Importantly, HER3 signaling has been shown to be associated with the resistance mechanism of anti-EGFR/HER2 therapies (Erjala et al., 2006; Engelman et al., 2007; Sergina et al., 2007; Yonesaka et al., 2019), and is emerging as a promising therapeutic target for EGFR-mutant NSCLC. This evidence concerns the gene ERBB3 and non-small cell lung carcinoma.